

## 第 92 卷 索引

<b>I</b>			
16S ribosomal RNA gene sequencing	891		
<b>A</b>			
<i>Achromobacter xylosoxidans</i>	869		
adjuvant	103		
AIDS	696		
amoxicillin	358, 386		
antibody	353		
antimicrobial stewardship	86		
antimicrobial therapy	115		
artesanate	690		
<i>Aspergillus</i> spp.	138		
avidin-biotin	126		
<b>B</b>			
<i>Bacillus cereus</i>	80		
bacteremia	133, 347, 869		
bactericidal	670		
BCG	705		
$\beta$ -hemolytic <i>Streptococcus</i>	115		
blood culture	46		
<b>C</b>			
<i>Campylobacter fetus</i>	884		
cellulitis	115		
chlorhexidine-alcohol	46		
Cholangiosis	371		
<i>Clostridium botulinum</i>	65		
colonization	678		
community acquired methicillin-resistant <i>Staphylococcus aureus</i>	115, 686, 855		
contamination rate	46		
<i>Cyclospora</i>	371		
<b>D</b>			
dengue fever	61, 863		
disinfectant	670		
disseminated nocardiosis	76		
		<b>E</b>	
		empyema	891
		erysipelas	115
		exfoliative toxin (ET)	663
		<b>F</b>	
		falciparum malaria	690
		family	61
		<b>G</b>	
		<i>Gemella haemolysans</i>	71
		genetic testing	331
		gram stain	76
		gumma	386
		<b>H</b>	
		<i>Haemophilus influenzae</i>	347
		<i>Helicobacter cinaedi</i>	133
		hepatitis B virus reactivation	568
		herpes zoster vaccine	103
		high-risk patient	51
		HIV	371, 556
		hospital	678
		<b>I</b>	
		IgA vasculitis	552
		immune reconstitution inflammatory syndrome	556
		immunochromatography	120, 126
		incubation period	538
		infant	65, 353
		infant botulism	65
		infected bulla	376
		infectious agents surveillance	365
		infective endocarditis	71, 686
		infliximab	878
		influenza	51
		inter-professional collaboration	568
		invasive aspergillosis	556

<b>J</b>		<b>P</b>	
Japanese	103	Panton-Valentine leukocidin (PVL)	663
Japanese spotted fever	547	paratyphoid fever	561
<b>K</b>		<i>Parvimonas micra</i>	891
Kawasaki disease	353	PCR-based open reading frame typing (POT)	663, 855
<b>L</b>		percutaneous lung biopsy	76
LAMP	701	<i>Plasmodium vivax</i>	538
laninamivir	51	pneumococcal disease	542
legal revision	365	pregnancy	869
<i>Legionella</i>	678	prevention	568
<i>Legionella pneumoniae</i>	701	primary central nervous system lymphoma (PCNSL)	696
<i>Leptospira Copenhageni</i>	144	prophylaxis	51
linen	80	public health institutes	365
long-acting neuraminidase inhibitor	51	<b>Q</b>	
<b>M</b>		questionnaire	331
malaria	533	quinine	690
malignant lymphoma	133	<b>R</b>	
matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS)	71, 884	rapid diagnostic test (RDT)	533
methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)	663	rapid growing mycobacteria	874
microscopic agglutination test	144	rapid HBsAg screening assay	126
minocycline	547	real time RT-PCR	120
murine typhus	391	renal angiomyolipoma	869
<i>Mycobacterium goodii</i>	874	Rheumatoid arthritis	878
<i>Mycobacterium haemophilum</i>	878	<i>Rickettsia typhi</i>	391
<i>Mycobacterium tuberculosis</i>	705	<b>S</b>	
mycotic aortic aneurysm	138	safety	103
<b>N</b>		SCCmec	686
necrotizing soft-tissue infection	380	sequence type	855
<i>Nocardia nova</i>	376	<i>Shewanella haliotis</i>	380
non-typeable	347	Spontaneous Bacterial Peritonitis	884
<i>norovirus</i>	120	Staphylococcal cassette chromosome <i>mec</i>	855
nosocomial infection	80	Staphylococcal enterotoxin	552
<b>O</b>		<i>Staphylococcus aureus</i>	552
oral antibiotic therapy	542	Sub-Saharan Africa	533
osteomyelitis	874	suspected primary syphilis	386
		syphilis	358
		syphilitic	386

	<b>T</b>		variable number of tandem repeat (VNTR)	705
Tokunoshima Island		547	vertebral osteomyelitis	542
toxoplasmic encephalitis		696	Vi antigen	561
travel history		538	virus inactivation	670
traveller		61	volunteer	533
tsunami lung		138		
typhoid fever		391, 561	<b>W</b>	
	<b>U</b>		water supply system	678
			Widal reaction	561
urinary antigen test		701	<b>Y</b>	
	<b>V</b>		<i>Yersinia pseudotuberculosis</i>	353
vaccine		347	<b>Z</b>	
vaccine efficacy		103	Zika virus infection	863

---